Interleukin-12 Antagonist [EPC]

65036 reported adverse events

Drugs of this class: USTEKINUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-12 Antagonist [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 8859
1 OFF LABEL USE 6660
2 PSORIASIS 5011
3 PRODUCT USE ISSUE 3664
4 CROHN^S DISEASE 3054
5 FATIGUE 2941
6 PAIN 2648
7 PRODUCT DOSE OMISSION ISSUE 2636
8 ARTHRALGIA 2513
9 HEADACHE 2467
See all common reactions for Interleukin-12 Antagonist [EPC]

Drugs of the Interleukin-12 Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 RED BLOOD CELL SEDIMENTATION RATE 109 0.5477
1 SWOLLEN JOINT COUNT INCREASED 272 0.5323
2 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 1070 0.4142
3 RHEUMATIC FEVER 316 0.4083
4 RHEUMATOID FACTOR POSITIVE 964 0.3752
5 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY 32 0.3678
6 CONTRAINDICATION TO VACCINATION 38 0.2249
7 ENTHESOPATHY 230 0.2128
8 DUODENAL ULCER PERFORATION 482 0.2040
9 PITYRIASIS RUBRA PILARIS 28 0.2014
See all enriched reactions for Interleukin-12 Antagonist [EPC]